Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (41-50 of 539) with videos related to

Pageof 54
Sort By:
Leukemia & Lymphoma|April 10, 2008
Cellular immune responses against the cancer-testis antigen SPAN-XB in healthy donors and patients with multiple myelomaChristian Frank, Michael Hundemer, Anthony D Ho, et al.
Annals of Hematology|June 24, 2023
Physical activity-related health competence and symptom burden for exercise prescription in patients with multiple myeloma: a latent profile analysisRea Kuehl, Maximilian Koeppel, Hartmut Goldschmidt, et al.
Psycho-Oncology|April 12, 2013
Psychosocial support in patients with multiple myeloma at time of diagnosis: who wants what?Jette Lamers, Mechthild Hartmann, Hartmut Goldschmidt, et al.
Hematological Oncology|August 26, 2017
Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approachMarc-Andrea Baertsch, Michael Hundemer, Jens Hillengass, et al.
Annals of Hematology|June 30, 2014
Extramedullary relapse after accidental head injury in a patient with multiple myelomaMaximilian Merz, Leonille Schweizer, Modar Kentar, et al.
Deutsches Arzteblatt International|March 22, 2022
Patients With Multiple Myeloma or Monoclonal Gammopathy of Undetermined SignificanceVanessa Piechotta, Nicole Skoetz, Monika Engelhardt, et al.
British Journal of Haematology|November 15, 2013
DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidineJerome Moreaux, Angelique Bruyer, Jean-Luc Veyrune, et al.
Cancer Treatment Reviews|May 22, 2012
Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairmentMeletios A Dimopoulos, Evangelos Terpos, Hartmut Goldschmidt, et al.
American Journal of Nuclear Medicine and Molecular Imaging|September 16, 2017
Quantitative analysis of <sup>18</sup>F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myelomaChristos Sachpekidis, Jens Hillengass, Hartmut Goldschmidt, et al.
Annals of Hematology|September 22, 2010
Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairmentUlrike Klein, Kai Neben, Thomas Hielscher, et al.
Pageof 54

Showing results (41-50 of 539) with videos related to

Sort By:
Pageof 54
Leukemia & Lymphoma|April 10, 2008
Cellular immune responses against the cancer-testis antigen SPAN-XB in healthy donors and patients with multiple myelomaChristian Frank, Michael Hundemer, Anthony D Ho, et al.
Annals of Hematology|June 24, 2023
Physical activity-related health competence and symptom burden for exercise prescription in patients with multiple myeloma: a latent profile analysisRea Kuehl, Maximilian Koeppel, Hartmut Goldschmidt, et al.
Psycho-Oncology|April 12, 2013
Psychosocial support in patients with multiple myeloma at time of diagnosis: who wants what?Jette Lamers, Mechthild Hartmann, Hartmut Goldschmidt, et al.
Hematological Oncology|August 26, 2017
Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approachMarc-Andrea Baertsch, Michael Hundemer, Jens Hillengass, et al.
Annals of Hematology|June 30, 2014
Extramedullary relapse after accidental head injury in a patient with multiple myelomaMaximilian Merz, Leonille Schweizer, Modar Kentar, et al.
Deutsches Arzteblatt International|March 22, 2022
Patients With Multiple Myeloma or Monoclonal Gammopathy of Undetermined SignificanceVanessa Piechotta, Nicole Skoetz, Monika Engelhardt, et al.
British Journal of Haematology|November 15, 2013
DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidineJerome Moreaux, Angelique Bruyer, Jean-Luc Veyrune, et al.
Cancer Treatment Reviews|May 22, 2012
Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairmentMeletios A Dimopoulos, Evangelos Terpos, Hartmut Goldschmidt, et al.
American Journal of Nuclear Medicine and Molecular Imaging|September 16, 2017
Quantitative analysis of <sup>18</sup>F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myelomaChristos Sachpekidis, Jens Hillengass, Hartmut Goldschmidt, et al.
Annals of Hematology|September 22, 2010
Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairmentUlrike Klein, Kai Neben, Thomas Hielscher, et al.
Pageof 54